ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

ADMA BIOLOGICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$11.07+0.39 (+3.65%)

Close on Oct 19, 2026

Market cap: $2.55B
P/E (TTM): 15.8
Dividend yield: –

ADMA BIOLOGICS, INC. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31
Depreciation & Amortization	8.00	7.70	7.60	6.40	4.80	3.20	2.40	2.60	1.50	0.40	0.47	0.25	0.21	0.18	0.22
Stock-Based Compensation	20	14	6.19	5.22	3.49	2.86	2.65	2.22	1.56	1.25	1.71	1.25	0.89	0.63	0.02
Deferred Income Taxes	11	-84	0	0	–	–	–	–	–	–	–	–	–	–	–
Change in Accounts Receivable	-108	-23	-12	13	-15	-9.77	2.08	2.49	-2.86	-0.09	-0.54	-0.38	0.04	0.04	0
Change in Inventory	-36	2.67	-9.63	-39	-43	-28	35	-5.99	0.59	-1.57	-1.74	-0.04	-0.40	-0.12	0.31
Change in Accounts Payable	2.33	4.15	3.84	0.80	1.36	1.90	3.27	-0.02	2.81	0.48	0.20	-0.94	1.61	-0.24	0.04
Change in Unearned Revenue	–	–	–	–	–	–	–	–	–	0	1.53	0	1.70	0	–
Operating Cash Flow	50	119	8.80	-60	-112	-102	-76	-63	-37	-18	-15	-15	-11	-6.90	-1.43
Capital Expenditures	-23	-8.23	-4.77	-14	-14	-13	-3.81	-2.10	-2.68	-0.07	-0.03	-2.32	-0.20	-0.12	0.00
Sale of Property, Plant & Equipment	–	–	–	–	0	0.00	0	–	–	–	–	–	–	–	–
Purchase of Investments	–	–	–	–	–	–	–	–	0	-16	-18	-1.72	-2.94	0	–
Investing Cash Flow	-22	-8.58	-4.98	-14	-14	-13	-3.81	-2.10	15	0.90	-1.74	-4.04	-3.13	-0.12	0.00
Share Repurchases	-32	0	0	–	–	–	–	–	–	–	–	–	–	-0.15	0
Stock Issued	–	0	0	65	121	131	48	43	39	13	10	0	27	17	0
Debt Issued	–	–	–	–	–	28	73	0	30	4.00	–	–	–	–	–
Debt Repaid	–	–	–	–	–	-14	-30	–	–	–	–	–	–	–	–
Financing Cash Flow	-44	-58	-39	109	121	144	80	43	61	17	10	9.80	28	19	1.29
Net Change in Cash	-16	52	-35	35	-4.83	29	0.00	-22	39	-0.53	-6.76	-8.95	14	12	-0.14
Free Cash Flow	28	110	4.03	-73	-126	-115	-80	-65	-40	-18	-15	-17	-11	-7.02	-1.43
Income Taxes Paid	20	9.39	0	0	–	–	–	–	–	–	–	–	–	–	–
Interest Paid	9.08	11	18	14	11	10	10	4.40	2.29	1.53	1.33	0.79	0.38	0.00	0.02

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 64.7%
Operating margin: 43.8%
Net margin: 33.0%
Return on equity, FY2025: 35.6%

Financial strength

Current ratio: 6.97
Debt to equity: 0.48
Debt to assets: 28.7%
Cash to current liabilities: 179.5%

Valuation

P/E ratio: 15.8
Price to sales: 4.98
Price to book: 6.25
Dividend yield: –